Altium Capital Management LLC Sells 252,000 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Altium Capital Management LLC reduced its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 36.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 432,000 shares of the company's stock after selling 252,000 shares during the period. Vera Therapeutics comprises 5.2% of Altium Capital Management LLC's portfolio, making the stock its 3rd biggest position. Altium Capital Management LLC owned about 0.68% of Vera Therapeutics worth $18,269,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Huntington National Bank bought a new stake in Vera Therapeutics during the 4th quarter valued at about $26,000. Summit Investment Advisors Inc. increased its holdings in Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares during the period. AlphaQuest LLC purchased a new stake in shares of Vera Therapeutics in the 4th quarter worth $34,000. Alliancebernstein L.P. grew its position in shares of Vera Therapeutics by 2.0% during the 4th quarter. Alliancebernstein L.P. now owns 40,350 shares of the company's stock worth $1,706,000 after buying an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after acquiring an additional 1,130 shares in the last quarter. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Price Performance

NASDAQ VERA traded up $0.66 on Tuesday, hitting $21.77. The company had a trading volume of 393,161 shares, compared to its average volume of 747,042. The company has a market capitalization of $1.39 billion, a PE ratio of -8.32 and a beta of 1.28. The company's fifty day moving average price is $25.82 and its 200-day moving average price is $36.33. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. As a group, analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Finally, Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $64.67.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.